Bio

As President & CEO at Turner Healthcare Quality Consulting, Inc., I lead engagements with biopharmaceutical clients in the development and implementation of health care quality strategy with the aim to optimize market access strategy and impact for prioritized brands. We work hard to understand biopharmaceutical clients’ pain points and opportunities and where we can help solve problems and deliver value. We help biopharmaceutical companies, particularly those that are small-to-medium size, “stand in the shoes” of their prioritized payer and provider (including pharmacy) customers. The value-based payment paradigm shift with the aim to progressively advance on the Quadruple Aim – the tenets of which are to improve patient experience, improve provider experience, improve population health outcomes, and do so at lower cost – compel the need for a quality strategy by organizations committed to the development of biopharmaceuticals in the quest of improving human health. Based on my 20 years as an executive in the pharmaceutical industry, working across a diverse range of functions (i.e., clinical development, medical affairs, market access, quality strategy), I gained strong marketplace knowledge of the challenges and opportunities confronting the biopharmaceutical industry to achieve optimized market access. This experience is complemented by my health policy and quality expertise, from a two-year health policy educational certificate program, four years in a healthcare quality strategy role at Johnson & Johnson, and almost two years as a senior executive at a non-profit, quality measure development organization in the Washington D.C. area.